Thalidomide and its sequelae

  title={Thalidomide and its sequelae},
  author={Michael Emanuel and Michael Rawlins and GordonW. Duff and Alasdair M. Breckenridge},
  journal={The Lancet},
Dec 16, 1961, became one of the most important dates in the calendar of modern therapeutics when The Lancet published a letter from W G McBride, an Australian obstetrician, describing the tragedy of congenital abnormalities caused by use of thalidomide in pregnancy. Before this, Widukind Lenz, a German paediatrician, had written to Chemie Grünenthal, the manufacturer of thalidomide, expressing his concerns about the potential of the drug to cause multiple birth defects, and presented his data… Expand
Trastuzumab, lapatinib and bevacizumab during pregnancy
It is advocated that treatment during pregnancy should be according to the standard as much as possible and based on available cohort studies, surgery and also chemotherapy (from 12–14 weeks gestation) is possible during pregnancy without impairment of fetal safety. Expand
Mental Disorders in People Affected by Thalidomide.
Mental disorders occur approximately twice as often in thalidomide-affected individuals as in the age-matched German population, which implies an underuse of psychosocial healthcare. Expand
Lump in the throat - a case study.
On examination, Jack, aged 66 years, presented to his general practitioner with a foreign body sensation in his throat and altered voice, which developed over 30 minutes, but on examination he had no itch or rash, or swelling of the tongue, lips, cheek or neck. Expand
Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.
  • V. Jordan
  • Medicine
  • British journal of clinical pharmacology
  • 2015
The essential aspects of animal models in the unanticipated development of an orphan medicine tamoxifen, used initially to treat late stage breast cancer, are focused on. Expand
Current Status of Pediatric Labeling in China and the near Future Efforts Needed for the Country
The dilemma of “therapeutic orphan” requires significant attention in China and calls for more efforts from pharmaceutical industries, regulatory agencies, and legislature in China to collaborate and find solution to improve the situation. Expand
The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
It was demonstrated that SNPs in HBG2 and HBS1L-MYB contributed significantly to thalidomide response in Chinese patients with β-thalassemia and that the cumulative number of minor SNP alleles may serve as good predictors of treatment response in this population. Expand
Promoting Patient Safety-Medication without Harm
  • 2018
Medication safety has been a major topic among pharmacists and other healthcare professionals throughout the world, both pharmaceutical care (PC) as pharmacovigilance (PV). While PV consists ofExpand
Pediatric drug regulation: International perspectives
Pediatric drug regulation in five of the largest international drug regulatory agencies is described and efforts at international cooperation and discussion in pediatric drug regulation are discussed. Expand
Drugs and Medical Devices: Adverse Events and the Impact on Women's Health.
It is recognized that women are still at risk for harm from unsafe medications and devices, and continued improvements in legislation that promotes inclusion of sex and gender into the design and analysis of research will improve safety for both men and women. Expand
Neonatal Pharmacotherapy: Legal and Regulatory Issues
Off-label and unlicensed use of medicines is high in the paediatric population and specifically high in neonatal/paediatric intensive settings with up to 90% of cases. This is associated with higher i


Thalidomide and Congenital Abnormalities
It is observed that the incidence of multiple severe abnormalities in babies delivered of women who were given the drug thalidomide during pregnancy, as an anti-emetic or as a sedative, to be almost 20%. Expand
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells, and experienced a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines. Expand
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor. Expand
A "pennurth of arsenic for rat poison": the Arsenic Act, 1851 and the prevention of secret poisoning.
In this country any chemist or druggist can furnish the means of self-destruction or murder for a few pence, and in too many instances have done so with the utmost indifference. The sale of a poisonExpand
New drugs and the Kefauver-Harris amendment.
  • J. Krantz
  • Medicine
  • The Journal of new drugs
  • 1966